What's moving in peptide science, decoded.
We monitor PubMed, FDA press releases, ClinicalTrials.gov, and the longevity press. Every item here is editorially reviewed before publish — no scraped summaries, no unreviewed AI output.
Why we don't publish 'where to buy' articles for research peptides
Half the peptide content online is vendor marketing with a journalism veneer. Here's our editorial position, why we hold it, and what it costs us.
Compounded semaglutide is gone. Here's what patients should know.
The FDA's semaglutide shortage-resolved declaration ended 503A and 503B compounding discretion in 2025. A year later, the clinical consequences are landing.
Orforglipron hits Phase 3 endpoint. The oral GLP-1 heads for FDA submission.
Eli Lilly's small-molecule oral GLP-1 agonist showed clinically meaningful weight loss and glycemic control in the ATTAIN and ACHIEVE trial programs. A pill version of the category is closer than it looked even six months ago.
The July 2026 FDA peptide advisory committee: what's on the agenda.
The PCAC hearing that will determine whether BPC-157, GHK-Cu, and 12 other peptides return to legal compounding is coming. Here's what the agenda looks like, what to watch, and what a yes-or-no ruling would actually mean for patients.
$499 Wegovy and $349 Zepbound: the cash-pay GLP-1 economy, decoded
NovoCare and LillyDirect have each carved out a direct-to-patient channel that brings semaglutide and tirzepatide within reach for uninsured patients. Here's what each program actually costs, what it gets you, and where the ceilings are.
Muscle loss on GLP-1s: what the 2025 evidence actually shows
A quarter to a third of the weight lost on semaglutide and tirzepatide is lean mass. The 2025 studies put sharper numbers on it and clarify what countermeasures actually help.
SURMOUNT-5: tirzepatide's efficacy edge over semaglutide, confirmed
The first head-to-head RCT of tirzepatide vs semaglutide for obesity reported 20.2% vs 13.7% mean weight loss at 72 weeks. What the trial settles, and what it doesn't.
Hims vs Ro vs Henry vs MEDVi: the telehealth GLP-1 matrix in April 2026
Four telehealth providers, four pricing structures, four clinical approaches. Here's how they compare on what actually matters — product, cost, intake, and ongoing care.
Resistance training on GLP-1s: the protocol actually supported by the 2025 data
The 'do resistance training to preserve muscle' advice is near-universal. What's actually supported by clinical trial data — and what's extrapolation.
HHS proposes pulling 14 peptides off FDA's Category 2 list. What happens now?
The February 2026 announcement reopens the compounding question for BPC-157, GHK-Cu, CJC-1295, and 11 others. The path from proposal to pharmacy shelves runs through July's advisory committee.
Every week
Get the news desk in your inbox.
Free. Weekly. Unsubscribe anytime.